<DOC>
	<DOCNO>NCT00243243</DOCNO>
	<brief_summary>The purpose study see medication ( Recombinant Coagulation Factor VIIa NovoSeven ) , normally use stop bleed person bleed disorder , low amount blood lose burn surgery .</brief_summary>
	<brief_title>Effect rFVIIa Peri-operative Blood Loss Patients Undergoing Major Burn</brief_title>
	<detailed_description>To identify clinical use Factor VIIa operate room reduce blood loss blood transfusion , determine Recombinant Factor VIIa ( rFVIIa ) pharmacokinetics burn patient , determine fFVIIa use reduce peri-operative blood loss patient undergoing excision great equal 20 percent total body surface area , determine efficacy drug burn patient undergo excision burn wound .</detailed_description>
	<mesh_term>Burns</mesh_term>
	<criteria>Male female Burn wound 1865 year age Scheduled excision burn wind least 20 percent TBSA Age great 65 year History blood coagulation disorder Taking anticoagulation medication Contraindication heparin therapy Pregnant nursing female Unstable angina MI within last 6 month Recent diagnosis DVT , stroke within last 6 month Renal failure require dialysis creatinine clearance le 25 ml/min Religious prohibition blood transfusion Have receive rFVIIa current hospitalization Previous enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Burns</keyword>
</DOC>